Aberdeen Group
BCRX icon

Aberdeen Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aberdeen Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$53.9M Buy
6,468,726
+1,157,855
+22% +$10.9M 0.07% 218
2026
Q2 		$53.1M Buy
5,310,871
+270,201
+5% +$2.44M 0.07% 218
2026
Q1 		$48M Buy
5,040,670
+4,127,077
+452% +$32.1M 0.08% 224
2025
Q4 		$7.13M Buy
+913,593
New +$6.6M 0.01% 661
2024
Q1 		– Sell
-504,528
Closed -$3.02M – 952
2023
Q4 		$3.02M Buy
+504,528
New +$2.92M 0.01% 742

Other funds holding BCRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
OP Asset Management
OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Aberdeen Group's BCRX Position: Q3 2026 in Review

Aberdeen Group increased its BioCryst Pharmaceuticals (BCRX) stake by 22% in Q3 2026, buying an estimated $10.9M and bringing the position to 6,468,726 shares worth $53.9M. The position accounts for 0.07% of the portfolio, ranked #218.

Aberdeen Group first reported a position in BCRX in Q4 2023 and has held it in 5 quarters since. 116 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Aberdeen Group held 6,468,726 shares of BioCryst Pharmaceuticals worth $53.9M as of Q3 2026.
  • Aberdeen Group bought 1,157,855 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $10.9M.
  • BioCryst Pharmaceuticals made up 0.07% of Aberdeen Group's portfolio in Q3 2026, its #218 holding.
  • Aberdeen Group first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.